PD-L1 inhibitors pharmacologically block the PD-1/PD-L1 interaction, thus enhancing immunologic response in destroying the cancer cells (Alsaab et al., 2017; Sharma and Allison, 2015). This evidence concerns the gene CD274 and cancer.